samedan logo
 
 
 
spacer
home > ebr > autumn 2009 > peptide potential
PUBLICATIONS
European Biopharmaceutical Review

Peptide Potential

 

Peptides, the most basic of building blocks in physiology, continue to grow in prominence among pharmaceutical manufacturers. With inherent abilities to block or enhance signal transfers in the human body, peptides, when harnessed as active pharmaceutical ingredients, can treat a host of metabolic diseases, cardiovascular and heart conditions, and neurodegenerative disorders.

Peptide-based drug targets are being identified at an increasingly rapid pace, both in terms of recently introduced therapies, and products in the development pipeline. In fact, a recent report by market and technology research firm Frost & Sullivan indicated that more than 40 approved peptide-based drugs are in use today, and approximately 400 are being developed to treat allergies, cancer, Alzheimer’s, Huntington’s and Parkinson’s diseases (1).

Peptide-based therapies tap into the direct hardwiring of human physiology, yielding substantial and far-reaching benefits to drug treatments and therapies. Moreover, developments in peptide manufacturing and implementation have made these amino acid compounds more accessible to the market in terms of cost, flexibility and effectiveness.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Hu oversees all non-GMP and GMP business divisions within the American Peptide Company (APC). He has been with APC for 18 years and he is tasked with keeping the organisation profitable and meeting growth objectives year after year. Gary spearheads the Total Peptide ManagementTM programme, a flagship initiative designed to help the pharmaceutical and life sciences industries bring new and innovative drugs to market faster. Specialising in business development, he emphasises a team approach to bring value and integrity to customers’ projects.
spacer
Gary Hu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

PHILADELPHIA – ASMS 2021 – (November 1, 2021) – Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography column.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement